Clinical Research of Tapering UDCA in PBC Patients With a Complete Response

PHASE4RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 21, 2020

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Primary Biliary Cholangitis
Interventions
DRUG

ursodeoxycholic acid

The two experimental groups will receive reduced dosage of UDCA at 10mg/Kg and 5mg/Kg everyday respectively, while the control group will receive standard dosage of UDCA.The treatment duration will be at least one year.

Trial Locations (1)

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER